| BARLESI, Fabrice |
PACIFIC-9, NCT05221840 / 2021-004346-37: A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 999 | Europe, Canada, Japan, US, RoW | Durvalumab, Oleclumab, Monalizumab, Placebo | AstraZeneca | Non-Small Cell Lung Cancer | 05/26 | 05/30 | | |
|
|
|
|
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Completed | 2 | 999 | Europe | AZD2014, AZD4547, AZD5363, AZD8931, Selumetinib, ARRY-142866, Vandetanib, CAPRELSA, Standard maintenance for squamous NSCLC, Pemetrexed, ALIMTA, Durvalumab, savolitinib, Olaparib, LYNPARZA | UNICANCER, Intergroupe Francophone de Cancerologie Thoracique, Fondation ARC, AstraZeneca | Non-small Cell Lung Cancer Metastatic | 12/18 | 12/23 | | |
| Active, not recruiting | 2 | 50 | Europe | Durvalumab | Intergroupe Francophone de Cancerologie Thoracique, IFCT, AstraZeneca | Non-small Cell Lung Cancer Stage IV | 11/23 | 10/25 | | |
MELROSE, NCT03865511: MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib |
|
|
| Active, not recruiting | 2 | 150 | Europe | TAGRISSO® 80mg (Osimertinib), Tumor biopsies, ctDNA analysis | Nantes University Hospital, AstraZeneca | Non-small Cell Lung Cancer | 01/25 | 01/25 | | |
| Recruiting | 2 | 122 | Europe | Live Bacterial Product - Akkermansia muciniphila | EverImmune, EverImmune SAS | Carcinoma, Renal Cell, Carcinoma, Non-Small-Cell Lung | 06/25 | 06/26 | | |
| Recruiting | 2 | 70 | Europe, US | IPH5201 + durvalumab + standard chemotherapy, Durvalumab, MEDI4736, IMFINZI, Carboplatin/Paclitaxel Carboplatin/Paclitaxel, as chemotherapy, Pemetrexed/Cisplatin Pemetrexed/Cisplatin as chemotherapy, Pemetrexed/Carboplatin Pemetrexed/Carboplatin as chemotherapy | Innate Pharma, Innate Pharma SA | Non Small Cell Lung Cancer | 06/25 | 09/26 | | |
| Active, not recruiting | 1/2 | 73 | Europe | PDC*lung01, Keytruda Injectable Product, Pembrolizumab, Alimta Injectable Product, Pemetrexed | PDC*line Pharma SAS | Non Small Cell Lung Cancer | 07/24 | 12/25 | | |
| Perol, Maurice |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) |
|
|
| Recruiting | 3 | 756 | Europe, US, RoW | Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 07/27 | 07/29 | | |
| Completed | 2 | 90 | Europe, US | avutometinib (VS-6766), avutometinib (VS-6766) and Defactinib, avutometinib (VS-6766) and VS-6063 | Verastem, Inc. | Non Small Cell Lung Cancer, KRAS Activating Mutation | 08/23 | 12/23 | | |
|
MOST plus, NCT02029001: Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment |
|
|
| Recruiting | 2 | 900 | Europe | Nilotinib (400 mg BID), Open cohort, Everolimus (10 mg QD), Closed cohort, Sorafenib (400 mg BID), Lapatinib (1500 mg QD), Pazopanib (800 mg QD), Olaparib (300 mg BID), Durvalumab + Tremelimumab | Centre Leon Berard, National Cancer Institute, France | Malignant Solid Neoplasms | 01/26 | 10/27 | | |
| Recruiting | 2 | 70 | Europe, US | IPH5201 + durvalumab + standard chemotherapy, Durvalumab, MEDI4736, IMFINZI, Carboplatin/Paclitaxel Carboplatin/Paclitaxel, as chemotherapy, Pemetrexed/Cisplatin Pemetrexed/Cisplatin as chemotherapy, Pemetrexed/Carboplatin Pemetrexed/Carboplatin as chemotherapy | Innate Pharma, Innate Pharma SA | Non Small Cell Lung Cancer | 06/25 | 09/26 | | |
| Recruiting | 2 | 60 | Europe | Amivantamab, Lazertinib, Zirabev | ETOP IBCSG Partners Foundation, Janssen Pharmaceuticals | Non Small Cell Lung Cancer | 03/26 | 09/26 | | |
| Completed | N/A | 179 | Europe, Canada, RoW | | Takeda | Non-small Cell Lung Cancer (NSCLC) | 02/23 | 02/23 | | |
PROFILER, NCT01774409: Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer |
|
|
| Recruiting | N/A | 10000 | Europe | Blood and tumor samples | Centre Leon Berard | Neoplasms | 07/25 | 07/26 | | |
EDHITO, NCT03948724: Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology |
|
|
| Active, not recruiting | N/A | 411 | Europe | Therapeutic education program, Usual Information | Institut Cancerologie de l'Ouest | Therapeutic Patient Education, Immune Checkpoint Inhibitors, Melanoma, Advanced Non-small Cell Lung Cancer, Renal Cell Carcinoma, Head and Neck Cancer, Immune-related Adverse Event | 08/23 | 08/24 | | |
| Completed | N/A | 209 | Europe | CANUT support, Anthropometric measures, Prehension strength measurement, QVA Questionnaire, QLQ C30 Questionnaire, Scratch & Snif Test, Taste Strip Test, 24 H feed back questionnaire, Condiment questionnaire, Tobacco questionnaire, Nutrition interview | Hospices Civils de Lyon | Breast Cancer, Gynecologic Cancer, Bronchial Cancer, Breast, Gynecological or Bronchial Cancer Treated With Intravenous Chemotherapy | 09/23 | 09/23 | | |
| Recruiting | N/A | 700 | Europe, Canada, US, RoW | | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Cancer | 03/27 | 03/27 | | |
| Cortot, Alexis |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
DIAL, NCT05255302 / 2021-006044-27: De-escalation Immunotherapy MAintenance Duration Trial for Stage IV Lung Cancer Patients with Disease Control After Chemo-immunotherapy Induction |
|
|
| Recruiting | 2/3 | 1360 | Europe | Pembrolizumab before randomization, Chemotherapy, Pemetrexed, Pembrolizumab after randomization | Intergroupe Francophone de Cancerologie Thoracique, IFCT | Metastatic NSCLC | 01/25 | 06/29 | | |
GFPC 06-2018, NCT04042558 / 2019-000727-41: A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies |
|
|
| Recruiting | 2 | 149 | Europe | Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab, Carboplatin + Pemetrexed + Atezolizumab | Centre Francois Baclesse, GFPC | NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation, ALK Gene Rearrangement Positive, ROS1 Gene Mutation | 10/21 | 06/25 | | |
ORBITAL, NCT04233021: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation |
|
|
| Active, not recruiting | 2 | 57 | Europe | Osimertinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation | 03/23 | 12/24 | | |
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients with Advanced ALK-positive Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 23 | Europe | Lorlatinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 01/25 | 01/25 | | |
| Recruiting | 2 | 119 | Europe | Encorafenib 75 MG, Binimetinib 15 MG | Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre | Non Small Cell Lung Cancer, BRAF V600E | 12/24 | 03/26 | | |
|
MELROSE, NCT03865511: MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib |
|
|
| Active, not recruiting | 2 | 150 | Europe | TAGRISSO® 80mg (Osimertinib), Tumor biopsies, ctDNA analysis | Nantes University Hospital, AstraZeneca | Non-small Cell Lung Cancer | 01/25 | 01/25 | | |
REPOROS, NCT06552234: Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC |
|
|
| Not yet recruiting | 2 | 30 | Europe | Repotrectinib | Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Groupe Français de Pneumo-Cancérologie, Hospices Civils de Lyon | NSCLC Stage IV, NSCLC, Stage III | 09/31 | 09/31 | | |
NCT04621188: Lorlatinib After Failure of First-line TKI in Patients with Advanced ROS1-positive NSCLC (ALBATROS) |
|
|
| Recruiting | 2 | 84 | Europe | Lorlatinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 03/25 | 01/26 | | |
| Active, not recruiting | 2 | 110 | Europe | Brigatinib 180 MG, ALUNBRIG, Carboplatin, Pemetrexed | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer, ALK Gene Mutation | 04/25 | 10/28 | | |
| Recruiting | 2 | 70 | Europe, US | IPH5201 + durvalumab + standard chemotherapy, Durvalumab, MEDI4736, IMFINZI, Carboplatin/Paclitaxel Carboplatin/Paclitaxel, as chemotherapy, Pemetrexed/Cisplatin Pemetrexed/Cisplatin as chemotherapy, Pemetrexed/Carboplatin Pemetrexed/Carboplatin as chemotherapy | Innate Pharma, Innate Pharma SA | Non Small Cell Lung Cancer | 06/25 | 09/26 | | |
RAMP 203, NCT05074810: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients |
|
|
| Recruiting | 1/2 | 153 | Europe, US | avutometinib and sotorasib, AMG 510, LUMAKRAS™, VS-6766, avutometinib and sotorasib and defactinib, VS-6063 | Verastem, Inc., Amgen | Non Small Cell Lung Cancer, KRAS Activating Mutation | 09/25 | 04/27 | | |
| Recruiting | 1/2 | 21 | Europe | EXL01 | University Hospital, Lille, Exeliom Biosciences | Non-Small Cell Lung Cancer | 10/28 | 10/28 | | |
NCT05752552: Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients with Advanced or Refractory Solid Tumours |
|
|
| Recruiting | 1 | 25 | Europe | DO-2 | DeuterOncology | Adult Solid Tumor, Advanced Solid Tumor, Refractory Tumor, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Lung Cancer, Hereditary Renal Papillary Cancer | 12/25 | 12/26 | | |
| Completed | N/A | 179 | Europe, Canada, RoW | | Takeda | Non-small Cell Lung Cancer (NSCLC) | 02/23 | 02/23 | | |
EmoVie_K2, NCT04556344: Effectiveness of an Educational Intervention Aimed at Increasing the Emotional Competencies of Patients Under Surveillance After Antineoplastic Treatment of Oesogastric or Bronchopulmonary Cancer |
|
|
| Recruiting | N/A | 86 | Europe | Emotional skills, Short free talk and relaxation | University Hospital, Lille, SCALab UMR CNRS 9193 | Digestive System Neoplasms, Thoracic Neoplasms | 10/23 | 10/23 | | |
CIRCULAR, NCT04912687: Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients |
|
|
| Recruiting | N/A | 580 | Europe | EGFR gene mutation analysis on liquid biopsy | Institut Bergonié, AstraZeneca | Non Small Cell Lung Cancer, Advanced Solid Tumor | 01/25 | 01/26 | | |
| Recruiting | N/A | 700 | Europe, Canada, US, RoW | | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Cancer | 03/27 | 03/27 | | |
| Recruiting | N/A | 100 | Europe | RNAseq, DNA NGS | Groupe Francais De Pneumo-Cancerologie, Takeda | Non-small Cell Lung Cancer, ALK Gene Rearrangement Positive | 06/27 | 06/27 | | |
ROSIE, NCT06053099: A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19) |
|
|
| Recruiting | N/A | 300 | Europe | Plasma ctDNA, FFPE blocks | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19, EGFR L858R | 10/31 | 10/31 | | |
| Recruiting | N/A | 500 | Europe | tissue biopsies, blood sampling, DNA banking | University Hospital, Lille, Institut Pasteur de Lille, University of Lille Nord de France | Lung Cancer | 03/32 | 03/32 | | |
| Wang, Shu |
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 |
|
|
| Recruiting | 3 | 366 | RoW | RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda | RemeGen Co., Ltd. | Breast Cancer | 06/24 | 12/24 | | |
| Active, not recruiting | 3 | 466 | Europe, Canada, Japan, US, RoW | tucatinib, ONT-380, placebo, T-DM1, Kadcyla | Seagen Inc., Seagen Inc., Seattle Genetics, Inc., Seagen Inc | HER2-positive Breast Cancer | 06/23 | 10/27 | | |
|
|
HLX10-006-GCneo, NCT04139135: A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer |
|
|
| Recruiting | 3 | 642 | RoW | HLX10, Recombinant humanized anti-PD-1 monoclonal antibody injection, Placebos | Shanghai Henlius Biotech | Gastric Cancer | 10/23 | 10/24 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
| Recruiting | 3 | 314 | RoW | Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Breast Cancer | 07/25 | 01/26 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases |
|
|
| Active, not recruiting | 2/3 | 301 | RoW | RC48-ADC, RC48, Lapatinib, Capecitabine | RemeGen Co., Ltd. | Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases | 07/24 | 12/24 | | |
NCT05576389: Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer |
|
|
| Enrolling by invitation | 2 | 94 | RoW | Camrelizumab+Fluzoparib | Peking University People's Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd. | Germline BRCA-mutated HER2-negative Breast Cancer | 04/24 | 12/26 | | |
NCT06592625: Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients |
|
|
| Not yet recruiting | 2 | 60 | RoW | SHR-A1811, Adebrelimab | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Untreated Early-stage or Locally Advanced Breast Cancer | 02/26 | 02/26 | | |
NCT04750122: Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for HER2 Positive Early Breast Cancer Patients |
|
|
| Recruiting | 1/2 | 46 | RoW | neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screenning, docetaxel and trastuzumab and pertuzumab, docetaxel and carboplatin and trastuzumab and pertuzumab | Peking University People's Hospital | HER2-positive Early Breast Cancer | 06/22 | 12/26 | | |
NCT04836156: Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients |
|
|
| Recruiting | 1/2 | 46 | RoW | neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer, docetaxel and carboplatin, docetaxel and epirubicin, neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer, docetaxel and cyclophosphamide, epirubicin and cyclophosphamide | Peking University People's Hospital | HER2-negative Early Breast Cancer | 06/22 | 12/26 | | |
NacHER2, NCT06700369: De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients |
|
|
| Recruiting | N/A | 519 | RoW | | Shu Wang | HER2-positive Breast Cancer | 12/28 | 12/31 | | |
NCT02691624: Study of the Change of Breast Cancer Patients' Upper Limb Lymphatic Drainage Pathway After Operation |
|
|
| Active, not recruiting | N/A | 100 | RoW | | Peking University People's Hospital | Lymphedema of Upper Arm | 05/16 | 12/21 | | |
| Recruiting | N/A | 380 | RoW | | Peking University People's Hospital | Triple Negative Breast Cancer | 12/28 | 12/28 | | |
NeoTNBCX, NCT06700382: Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC |
|
|
| Recruiting | N/A | 1166 | RoW | capecitabine | Shu Wang | Triple Negative Breast Cancer | 12/31 | 12/31 | | |
nonPHER, NCT06693037: Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy |
|
|
| Recruiting | N/A | 2092 | RoW | | Shu Wang | HER2-positive Breast Cancer | 12/31 | 12/31 | | |
| Recruiting | N/A | 2806 | RoW | neratinib | Shu Wang | HER2-positive Breast Cancer | 12/31 | 12/31 | | |
NCT03640117: The Value of Geriatric Assessments in Older Patients With Breast Cancer |
|
|
| Recruiting | N/A | 200 | RoW | | Peking University People's Hospital | Aging, Breast Cancer, Chemotherapeutic Toxicity, Survival | 05/22 | 05/25 | | |
NCT03791853: Light-CT in the Diagnosis of Breast Tumor and Lymph Node |
|
|
| Recruiting | N/A | 150 | RoW | Light-CT | Peking University People's Hospital | Breast Neoplasms | 12/22 | 12/23 | | |
PROOF, NCT02430103: Study of Preservation of Ovarian Reserve During Chemotherapy for Young Breast Cancer Patients |
|
|
| Active, not recruiting | N/A | 349 | RoW | Goserelin 3.6 MG, Zoladex | Peking University People's Hospital | Breast Cancer | 12/23 | 12/24 | | |
NCT03105570: The Oncological Safety and Cosmetic Outcome of Areola Sparing Mastectomy : a Single Arm, Prospective, Cohort Study |
|
|
| Recruiting | N/A | 145 | RoW | Areola Sparing Mastectomy, Nipple coring | Peking University People's Hospital | Breast Neoplasms | 05/24 | 05/24 | | |
| Recruiting | N/A | 190 | RoW | Imatinib, treat | Xijing Hospital | GIST | 09/24 | 09/25 | | |
NCT04996615: Artificial Intelligence Analysis for Magnetic Resonance Imaging in Screening Breast Cancer in High-risk Women |
|
|
| Recruiting | N/A | 5000 | RoW | no intervention | Peking University People's Hospital | Breast Cancer, Magnetic Resonance Imaging | 09/25 | 09/25 | | |
NCT04824378: Study on Classification Method of Indocyanine Green Lymphography Based on Deep Learning |
|
|
| Recruiting | N/A | 200 | RoW | No Intervention. | Peking University People's Hospital | Breast Cancer Related Lymphedema, Deep Learning | 10/22 | 10/22 | | |
NCT05634798: An Observational Study Based on Endometrial Cancer Risk Screening Model |
|
|
| Recruiting | N/A | 2000 | RoW | no intervention | Peking Union Medical College Hospital | Endometrial Neoplasms | 12/23 | 12/23 | | |
| Hangody, Laszlo |
| Active, not recruiting | N/A | 200 | Europe, US, RoW | Hyalofast, Microfracture | Anika Therapeutics, Inc. | Defect of Articular Cartilage | 06/25 | 06/26 | | |
| Landherr, Laszlo |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Duruisseaux, Michael |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 3 | 170 | Europe, Canada, Japan, US, RoW | Selpercatinib, LY3527723, LOXO-292, Placebo | Loxo Oncology, Inc., Eli Lilly and Company | Carcinoma, Non-Small-Cell Lung | 05/27 | 08/32 | | |
| Recruiting | 2 | 250 | Europe, Canada, Japan, US, RoW | zenocutuzumab (MCLA-128), bispecific, MCLA-128 | Merus N.V. | Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion | 12/26 | 12/26 | | |
| Active, not recruiting | 2 | 50 | Europe | Durvalumab | Intergroupe Francophone de Cancerologie Thoracique, IFCT, AstraZeneca | Non-small Cell Lung Cancer Stage IV | 11/23 | 10/25 | | |
| Active, not recruiting | 2 | 55 | Europe | Nivolumab, BMS-936558-01 | European Organisation for Research and Treatment of Cancer - EORTC, ETOP IBCSG Partners Foundation | Thymoma Type B3, Thymic Carcinoma | 12/23 | 07/24 | | |
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients with Advanced ALK-positive Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 23 | Europe | Lorlatinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 01/25 | 01/25 | | |
NCT04621188: Lorlatinib After Failure of First-line TKI in Patients with Advanced ROS1-positive NSCLC (ALBATROS) |
|
|
| Recruiting | 2 | 84 | Europe | Lorlatinib | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer Metastatic | 03/25 | 01/26 | | |
| Active, not recruiting | 2 | 110 | Europe | Brigatinib 180 MG, ALUNBRIG, Carboplatin, Pemetrexed | Intergroupe Francophone de Cancerologie Thoracique | Non Small Cell Lung Cancer, ALK Gene Mutation | 04/25 | 10/28 | | |
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination |
|
|
| Recruiting | 1/2 | 576 | Europe, US, RoW | MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy | Merus N.V. | Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer | 03/26 | 03/27 | | |
| Completed | N/A | 179 | Europe, Canada, RoW | | Takeda | Non-small Cell Lung Cancer (NSCLC) | 02/23 | 02/23 | | |
| Completed | N/A | 209 | Europe | CANUT support, Anthropometric measures, Prehension strength measurement, QVA Questionnaire, QLQ C30 Questionnaire, Scratch & Snif Test, Taste Strip Test, 24 H feed back questionnaire, Condiment questionnaire, Tobacco questionnaire, Nutrition interview | Hospices Civils de Lyon | Breast Cancer, Gynecologic Cancer, Bronchial Cancer, Breast, Gynecological or Bronchial Cancer Treated With Intravenous Chemotherapy | 09/23 | 09/23 | | |
| Recruiting | N/A | 260 | Europe | Blood sampling | Hospices Civils de Lyon | All Types of Solid Cancer | 05/28 | 05/28 | | |
| Recruiting | N/A | 600 | Europe | Solicitation for lung cancer screening, added exams to the usual lung cancer screening | Hospices Civils de Lyon | Lung Cancer | 09/24 | 09/24 | | |
DRACONIS, NCT06781905: Description of Neurocognitive and Psychiatric Disorders Associated with Targeted Therapies Used in the Treatment of Lung Cancers with ALK/ROS1 Fusion and Their Impact on Patients' Quality of Life: Construction of an Experimental Patient-researcher Collaborative Care and Research Pathway |
|
|
| Not yet recruiting | N/A | 20 | Europe | Assessments of neuropsychiatric, neurocognitive and psychosocial alterations | Hospices Civils de Lyon | Metastatic Lung Cancer, Metastatic Lung Cancer with ALK/ROS1 Fusion | 05/27 | 05/27 | | |
ONCOPRO, NCT03787056: Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients |
|
|
| Recruiting | N/A | 410 | Europe | Blood draws | Hospices Civils de Lyon | Cancer, Breast Cancer, Gastric Cancer, Renal Cancer, Prostate Cancer, Melanoma, Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer, Glioblastoma, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, B-cell Lymphoma | 01/28 | 01/28 | | |
MONITOR, NCT04605146: Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy |
|
|
| Recruiting | N/A | 100 | Europe | Tele-monitoring | Hospices Civils de Lyon | Melanoma, Lung Cancer, Renal Cancer | 11/28 | 11/28 | | |
IMMUCARE-BASE, NCT03989323: A Clinical and Biological Prospective Database of Patients Treated With Anticancer Immunotherapy and Follow up of Their Immune-related Adverse Events irAE |
|
|
| Recruiting | N/A | 2000 | Europe | Estimation of the incidence of the irAE | Hospices Civils de Lyon | Cancer | 07/29 | 07/29 | | |
| Shi, Yanxia |
PERS, NCT03006614: Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer |
|
|
| Recruiting | 3 | 320 | RoW | NVB, vinorelbine, EPI, epirubicin, DDP, cisplatin, CAP, capecitabine, GEM, gemcitabine, H, Trastuzumab, CTX, cyclophosphamidem, T, docetaxel | Shi Yanxia | Breast Cancer Model, Effects of Chemotherapy, Breast Cancer | 03/18 | 03/23 | | |
NCT05244577: Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer |
|
|
| Recruiting | 3 | 75 | RoW | Olanzapine Tablets, Olanzapine, Placebo | Shi Yanxia | Olanzapine, CINV, Testicular Cancer by AJCC V6 and V7 Stage, Cisplatin | 12/23 | 03/24 | | |
B2023-686-01, NCT06268652: Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer |
|
|
| Recruiting | 3 | 302 | RoW | Organoid-guided personalized treatment, OGPT, Gemcitabine, Gemzar, Capecitabine, Xeloda, Vinorelbine, Navelbine, Eribulin, Halaven | Sun Yat-sen University | Breast Cancer, Refractory Breast Carcinoma | 02/26 | 01/28 | | |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
| Recruiting | 3 | 314 | RoW | Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Breast Cancer | 07/25 | 01/26 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Recruiting | 2 | 120 | RoW | TQB3616 capsules, Fulvestrant injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HR-positive, HER2-negative Advanced Breast Cancer | 01/23 | 01/23 | | |
| Recruiting | 2 | 120 | RoW | TQB3616 capsules, Fulvestrant injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | HR-positive, HER2-negative Advanced Breast Cancer | 01/23 | 01/23 | | |
NCT06768931: Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer |
|
|
| Not yet recruiting | 2 | 192 | RoW | Biolosion (oral probiotic compound preparation) | Sun Yat-sen University | Breast Cancer, Triple Negative Breast Cancer (TNBC), Early Stage Breast Cancer, Immunotherapy, Probiotic | 01/30 | 02/35 | | |
NCT05760053: Toripalimab Plus Etoposide and Platinum-based Chemotherapy for Genitourinary Small Cell Carcinoma |
|
|
| Recruiting | 2 | 33 | RoW | EP/EC+PD-1, Etoposide, Cisplatin or Carboplatin, plus Toripalimab | Sun Yat-sen University | Toripalimab, First-line Treatment | 02/25 | 02/26 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT06639347: A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma |
|
|
| Recruiting | 1/2 | 90 | RoW | SHR-A2102, Adebrelimab injection, SHR-8068 injection | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Urothelial Carcinoma | 05/27 | 05/27 | | |
NCT05245058: SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors |
|
|
| Recruiting | 1 | 150 | RoW | SPH5030 tablets | Shanghai Pharmaceuticals Holding Co., Ltd | HER2-positive Advanced Solid Tumors | 12/24 | 12/24 | | |
| MAZIERES, Julien |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
